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Abstract: Stathmin1 (STMN1) has been proposed as a possible prognostic marker and a potential therapeutic target for some cancers.
We aimed to analyze the changes in autophagy, invasion, apoptosis-related genes in prostate cancer (PCa) cell line (PC-3), after small
interfering RNA (siRNA)-mediated STMN1 silencing, and also the relationships of STMN1 expression, clinicopathological parameters,
and survival (OS) in PCa cases.
The STMN1 expressions were analyzed, immunohistochemically, in formalin-fixed paraffin-embedded 75 PCa and 15 benign
prostatic hypertrophy (BPH) tissues. The correlation between the levels of expression STMN1, clinicopathological features, and OS
was determined in PCa cases. The siRNA-mediated STMN1 incubated PC-3 cells were transfected and compared to negative control
siRNAs. We determined mRNA levels in autophagy, invasion, and apoptosis genes with the combination of reverse transcriptionpolymerase chain reaction (RT-PCR) and western blotting in PC3 cell lines after STMN1 silencing.
It was determined that STMN1 was overexpressed significantly in PCa cases, immunohistochemically. The overexpression of STMN1
was significantly correlated with the high-grade Gleason score, and it was associated with a worse prognosis of PCa cases according
to the Kaplan–Meier survival analysis (p < 0.05). Significant silencing in STMN1 was determined (87.5%) after siRNA applications.
Especially, invasion genes such as claudin 7, fibroblast growth factor 8, hypoxia-inducible factor 1 subunit alpha, hepatocyte growth
factor, matrix metallopeptidase 2, 7 genes, markedly, decreased by siRNA-mediated STMN1silencing. STMN1 silencing was determined
to significantly increase caspase 3 protein expression by using western blot analysis (p < 0.001). Although STMN1 silencing did not have
a significant effect on the induction of apoptosis and autophagy-related genes in PCa cells, it was shown to affect apoptotic mechanisms
through the caps3 protein.
siRNA-mediated STMN1 silencing decreases proliferation in the PCa cell line. It is thought that STMN1 can serve as a potential
therapeutic target in the advanced stage-PCa, especially.
Key words: Prostate cancer, Stathmin1, siRNA silencing, autophagy, invasion, apoptosis

1. Introduction
Prostate cancer (PCa) is one of the most common
malignancies in men with hormonal factors that play
a role in the pathology and is generally a disease of the
elderly man (Siegel et al., 2020). PCa is known to be 10.6%
of all cancers, in 2020. At the time of diagnosis, 76% of the
cases are in the locally advanced stage, 13% with regional
lymph nodal involvement, and 6% distant metastasis. The
recurrence develops in about 40%–50% after first local
(i.e. prostatectomy or radiation) treatments in the locally
advanced stage. Although androgen deprivation therapy

(ADT) is a cornerstone for the management of advanced
PCa, sensitivity to ADT will determine the course of the
disease (Vlajnic et al., 2021). The androgen receptor (AR)
signaling becomes resistant to ADT within a few years;
cytotoxic therapies are also included in the management
of the advanced stage of PCa. ‘High-risk’ PCa often
progresses to castration-resistant PCa. The 5-year survival
of PCa in advanced stages is about 30.2%. Microtubuletargeting agents, such as taxanes, are the first option in
treatments of advanced stage PCa. Without microtubule
growth and assembly, the mitotic spindle cannot form and
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the cell cycle ceases. Taxanes decrease depolymerization
of β-tubulin during the mitotic cycle, resulting in mitotic
arrest and following cell death (NCCN, 2021). Taxanes kill
prostate cancer cells through this mechanism and prevent
proliferation in PCa.
Some signaling pathways such as phosphoinositide
3-kinase (PI3K) and hedgehog are activated during the
metastatic process and resistant to drugs in the treatment
of PCa. In these pathways, cyclin-dependent kinases
(CDKs), mitogen-activated protein kinases (MAPKs),
phosphoinositide 3-kinase (PIK3), protein kinase A (PKA),
c-Jun N-terminal kinase (JNK), and Ca+2/calmodulindependent protein kinases (CamKs)/phosphate signaling
pathways, are regulated by stathmin1 (STMN1) (MurilloGarzón et al., 2017). STMN1, also known as an oncoprotein,
is an important cytoplasmic phosphoprotein that regulates
cellular microtubule dynamics. STMN1 stimulates
microtubule depolymerization by sequestering tubulin
and inducing catastrophes (Howell et al., 1999; Yan et al.,
2018). In addition, STMN1 has a role in the cell signaling
pathway. STMN1 contributes to a malignant phenotype
characterized by a high proliferative index (Ghosh et al.,
2007). High STMN1 expression has been associated with
poor prognosis in many different tissue-derived cancer
types such as hepatoma, cholangiocarcinoma (Watanabe
et al., 2014). In previous studies, both in vivo and in vitro,
it has been shown that the proliferation, invasion rate can
be reduced by genetically silencing STMN1 with siRNAs
in mesothelioma, gastric cancer, colon cancer cell lines
(Kimberly et al., 2015).
Autophagy and energy metabolism are strongly
associated with the cell cycle. Abnormal autophagyapoptosis mechanisms are closely associated with the
developments of some cancer and autoimmune diseases.
Autophagy functions nearly like a tumor suppressor
gene (TSG) in the early stages of tumor genesis. Often,
malignancy occurs via the inhibition of autophagy
mechanisms. It has been shown that autophagy can be
induced in the PCa cell line through the down-regulation
of methyltransferases (KMT) and demethylases (KDM),
which are important epigenetic histone modifiers (Sha et
al., 2020).
The detection of the molecular changes in the invasion,
proliferation, formation of PCa would determine the
essential goals of the treatment. In the literature, there
are no studies investigating autophagy, apoptosis, and
invasion mechanisms in the pharmacological inhibition
of STMN1, which will increase the effect of microtubule
inhibitors used in the treatment of PCa and at the same
time, reduce tumor proliferation (Mistry et al., 2005).
STMN1 has been proposed as a possible prognostic
marker and a potential therapeutic target for some
cancers (Hiıeh et al., 2010, Watanabe et al., 2014). Based
on the aforementioned studies, we proposed a hypothesis;
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STMN1 expression may be a regulatory step in the
pathophysiology of the formation and spread of PCa, and
the activities of STMN1 can be knockdown by STMN1
silencing with siRNAs. In this study, we investigated
whether siRNA-mediated STMN1 silencing in PC3 cell
lines affects autophagy, invasion, apoptosis-related gene
panels, and whether the expression of STMN1 can be
evaluated as a prognostic marker in PCa cases.
2. Materials and methods
2.1. Case selection
Biopsy materials of 90 patients, 75 of whom were diagnosed
with PCa and 15 of whom were diagnosed with benign
prostatic hypertrophy (BPH) as the control group, were
included in the study. Before the study, Ethics Committee
approval was obtained to employ the retrospective medical
data of patients that were treated between 2009 and 2017 in
our university, medical oncology department. The paraffin
blocks of prostate tissues (transurethral resection (TUR)
samples) were obtained from the pathology department of
the faculty of medicine of our university. Specimens were
divided into 6 groups according to the Gleason score (GS)
system of WHO 2016; benign prostate hyperplasia (BPH),
as control group, grade group 1 (GS ≤ 6), grade group 2
(GS = 7 (3+4)), grade group 3 (GS = 7 (4+3)), grade group
4 (GS = 8), and grade group 5 (GS = 9–10) (NCCN, 2021).
2.2. Tissue samples and immune histochemistry
5-µm-thick paraffin block sections of the tissues fixed with
routine formalin buffer were transferred to poly-lysine
slides. These were processed in an automated staining
device STMN1 (Mouse monoclonal Ig G, 1/200, BOSTER/
USA) staining. The preparations were inspected, assessed,
and photographed with a Leica DM500 microscope. The
histoscores were determined based on the intensity (0.1:
<25%, 0.4: 26%–50%, 0.6: 51%–75%, 0.9: 76%–100%)
and severity of immune reactivity (0: no, +0.5: very little,
+1: little, + 2: medium, +3: severe) (Figures 1A–1D). The
histoscores were calculated with the “intensity X severity”
formula (Chen et al., 2012). The STMN1 histoscores were
categorized into two subgroups: those that were lower and
higher than median values.
2.3. Cell culture and siRNA transfection
To evaluate the utility of STMN1 gene silencing as a
therapeutic target, the effect on apoptotic, invasions,
and proliferation-related gene expressions of STMN1
siRNA transfection in PC-3 cell lines was analyzed.
Human PC-3 cells (ATCC® CRL-1435™) were grown
as monolayers in the RPMI-1640 medium (Cat. No.
R0883, Sigma-Aldrich, Germany) with 10% fetal
bovine serum (FBS; Cat. No. F6178, Sigma-Aldrich,
USA), 100 µg/mL–1 streptomycin and 40IU/mL–1
penicillin. PC-3 cell lines were incubated with 95%
air plus 5% CO2 at 37° (Nuve, Turkey). For siRNA
transfection of PC-3 cells, The HiPerfect® transfection
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reagent (Cat. No. 301704, Qiagen, Germany) was
employed with 5 µg of STMN1-siRNAs (per 35 mm
culture dish) (Cat. No. GS3925, Qiagen, USA) or
negative control siRNA (Cat. No. 1027280, Qiagen,
USA) on 6-well cell culture plates at a state of 70–80
confluency. Transfection was done from 36 to 48 h
after transfection. To confirm transfection efficiencies
and suppression of STMN1-RNA in PC-3 cells were
performed by qRT-PCR (with Cat. No. PPH14448B
primers, Qiagen, Germany). qRT-PCR results were
calculated as the percentage of siRNA silencing with
the ΔΔCT mean = ΔCT STMN1-siRNA - ΔCT negative
control; fold change = 2–ΔΔCT; percentage of silence =
100 × (1-fold change) formula.
2.4. qRT-PCR analysis
Total cellular RNA was isolated from PC-3 cells with the
Gene Jet RNA Purification kit (Cat. No. K0731, Thermo
Scientific, Lithuania) according to the manufacturer’s
protocols. The RNA pellet was resuspended in 10–30

μL nuclease-free water. The RNA samples were reverse
transcripted the complementary DNA (cDNA) with a
High-Capacity cDNA Reverse Transcription Kit (Cat.
No. 4368814, Applied Biosystems, USA) and a thermal
cycler (Veriti, Applied Biosystems, Singapore) at 25 °C
for 10 min, 37 °C for 120 min, and 85 °C for 5 min.
SYBR green-based autophagy (Cat. No. HATPL-I, Human
Autophagy Primer Library, RealTimePrimers.com),
apoptosis (Cat. No. HPA-I, Human Apoptosis Primer
Library, RealTimePrimers.com), and invasion panels
(Cat. No. HTIM-I, Human Invasion Primer Library,
RealTimePrimers.com) were used for qRT-PCR analysis.
The qRT-PCR was conducted on an Applied Biosystem
7500 Fast system (Applied Biosystems, Foster City, CA,
USA) using universal SYBR green supermix (Cat. No.
172-5121, Bio-Rad, USA) for 41 genes selected from
three panels. Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) (Cat. No. QT00079247, Qiagen, USA) was used
as an internal standard. The 2-∆∆CT method was employed
to determine the gene expression differences after the

Figure 1. Histopathological evaluation for stathmin1 (STMN1). A) STMN1 (+) expression evaluation in the control group (Haematoxylin
& Eosin (HE) X200), Immunoperoxidase X 200); B) STMN1 immunoreactivity in Grade 1 prostate acinar adenocarcinoma group
(Haematoxylin & Eosin (HE) X 100), Immunoperoxidase X 100); C) STMN1 immunoreactivity in Grade 2 prostate acinar adenocarcinoma
group (Haematoxylin & Eosin (HE) X 100), Immunoperoxidase X 100); D) STMN1 immunoreactivity in Grade 3 prostate acinar
adenocarcinoma group (Haematoxylin & Eosin (HE) X 100), Immunoperoxidase X 100); E) STMN1 immunoreactivity in Grade 4
prostate acinar adenocarcinoma group (Haematoxylin & Eosin (HE) X 100), Immunoperoxidase X 100); F) STMN1 immunoreactivity
in Grade 5 prostate acinar adenocarcinoma group (Haematoxylin & Eosin (HE) X 100), Immunoperoxidase X 100).
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qRT-PCR analysis. We repeated PCR measurements three
times, and the reported measurements were based on
these triplicate analyses.
2.5. Western blotting
Homogenization of the cells was performed on ice 1:10 (w/v)
in a buffer containing 50 mM Tris (pH 7.4), 0.1 mM NaCl, 1%
Triton X-100, 5 mM EDTA, 1.0 mM phenylmethylsulfonyl
fluoride, 10 mg/mL aprotinin and 10 mg/mL leupeptin.
The measurement of protein concentration for each
sample was performed according to the Lowry procedure
using a protein assay kit (Sigma, St. Louis, MO, USA), and
western blotting was performed. Separated proteins with
SDS polyacrylamide gel electrophoresis were transferred
to nitrocellulose membranes (Santa Cruz Biotechnology,
Inc., Texas, and USA). Nitrocellulose blots were blocked
with 5% dry milk and probed with Caspase 3 (sc-7272,
Santa Cruse Biotechnology, Texas, USA) and Lc-3 (sc398822, Santa cruse) primary antibodies at a dilution
of 1:500. The blots were washed and incubated for 1 h
with a secondary antibody, antimouse or antirabbit Ig
peroxidase-conjugated (Santa Cruz Biotechnology, Inc.,
Texas, and the USA) at a dilution of 1:500. Specific binding
was detected with chemi-glow detection reagents using
chemiluminescent detection. The relative amount of
immunoreactive bands on Western blots was quantified
in arbitrary units by scanning blots using a computerized
software program (LabWorks 4.0; UVP, Inc., Cambridge,
UK). Primary human anti-Beta actin and secondary
antimouse antibodies were used to monitor Beta-actin
expression as a loading control.
2.6. Statistical analysis
SPSS (IBM corp. Armonk, NY, USA) version 22 was
employed in statistical analyses. The collected data were
presented as mean ± standard deviation. Chi-squared test
statistics were used to compare categorical measurements
between groups. The Mann–Whitney U test was used
to compare numerical measurements that did not show
normal distribution between them. In comparison, the
Kruskal–Wallis test was used for the variables between
more than two groups. Spearman/Pearson correlation and
Student’s t-test were used to determine the parameters
affecting the median overall survival (OS). Survival curves
were calculated according to the Kaplan–Meier method
using Cox regression, and differences between curves
were evaluated using the log-rank test. The median OS was
calculated from the date of diagnosis to the date of death or
last follow-up. ROC analysis was performed to determine
the cutoff value for the value of STMN1 expression. The
qRT-PCR data were analyzed with the ΔΔCt module at the
Qiagen Gene Globe Data Analysis Center portal (http://
www.qiagen.com/us/shop/genesand-pathways/dataanalysis-center-overview-page/). The qRT-PCR module
transformed the threshold cycle (Ct) values to determine
gene expressions. The findings in the 95% confidence
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interval (CI) were considered statistically significant (p <
0.05).
3. Results
3.1. STMN1 expression in prostate cancer tissue by
immunohistochemistry
STMN1 was immune reactive in PCa and BPH tissues
as a control group (which is diagnosed as BPH disease).
STMN1 overexpression was statistically significantly
increased in PCa tissues compared to BPH tissues (p
= 0.001) as shown in Figure 1 and Table 1. The general
clinical characteristics of the patients are shown in Table 2.
The cutoff value of STMN1 in cases’ tissues with PCa was
tested with the ROC (Receiver Operation Characteristics)
curve. For the cutoff value of STMN1, AUC (area under
the curve) = 0.848 ± 0.044 (CI % 95: 0.763-0.934) (p <
0.001) and 0.7 were taken as cutoff value (sensitivity 68%
and specificity 100%) as shown in Figure 2A. We defined
< 0.7 CD1 as a low (L-STMN1) group and ≥ 0.7 CD1 as a
high (H-STMN1) group. General clinical features of cases
according to STMN1 expression are shown in Table 3.
There was a statistically significant positive correlation
between the overexpression of STMN1 and high-grade
Gleason score, the value of lactic dehydrogenase enzyme
(LDH) (Pearson’s r = 0.488, p < 0.001, Pearson’s r= 0.207,
p < 0.05, respectively). A negative correlation was also
observed between OS and STMN1 expression (Pearson’s
r = -0.420, p = 0.042). No significant correlation was found
between STMN1 expression and other parameters (grades,
age, pretreatment prostate-specific antigen (PSA) value,
last visit-PSA value, stage) are shown in Table 4.
3. 2. Survival evaluation
The median follow-up time was 75 (17-96) months, and the
median OS was 87 months (CI 95%: 65.45-108.54) in the
H-STMN1group. Although it was not reached the median
OS value in the L-STMN1 group statistically significant
Table 1. The relationship stathmin1 (STMN1)
immunoreactivity histoscore of paraffin block
prostate tissue specimens for each group
compared with a control group.
Group

STMN1*

p-value

Control

0.48 ± 0.16

Grade 1

0.68 ± 0.35

0.610

Grade 2

1.18 ± 0.62

0.010

Grade 3

1.24 ± 0.72

0.017

Grade 4

1.39 ± 0.80

0.009

Grade 5

1.48 ± 0.87

0.008

-

*Histoscore (prevalance × severity): *Mean
value ± SD, One-way ANOVA used
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Table 2. The relationship between clinical features and
stathmin1 (STMN1) expression rates.
Variables

n, (%)

STMN1*

Age

p-value
0.030

<65 years

17 (18.9%) 0.73 ± 0.11

≥65 years

73 (81.1%) 1.15 ± 0.75

Stage

0.162

Local advanced

35 (46.7%) 1.07 ± 0.63

Advanced

40 (53.3%) 1.31 ± 0.80

Perineurol invasion

0.970

Positive

35 (46.7%) 1.23 ± 0.83

Negative

40 (53.3%) 1.16 ± 0.64

Angiolymphatic invasion
Positive

31(41.3%) 1.31 ± 0.79 0.246

Negative

44(58.7%) 1.11 ± 0.68
0.010

Risk group-Gleason Scoreπ
≥7

45 (60%)

1.37 ± 0.11

<7

30(40%)

0.93 ± 0.10

Status of progression

0.528

Present

23(30.7%) 1.23 ± 0.75

Absent

52 (69.3%) 1.10 ± 0.69

Location of metastases

0.045

Bone metastases

25 (33%)

1.27 ± 0.78

Lung metastases
Multiple visceral
involvement
Nodal involvement

2 (2.6%)

1.35 ± 0.63

8 (10.6%) 1.86 ± 0.83
5 (6.6%)

0.6 ± 0.273

*mean ± SD, π: According to AJCC 8 ≥ 7: Very high, high, and
unfavorable intermediate risk group, < 7: Very low, low, and
favorable intermediate risk group.

correlation was found between STMN1 groups (H/L) for
the median OS (p = 0.025) as shown in Figure 2B.
3. 3. siRNA transfection efficiency analysis
The mRNA expressions of STMN1 in siRNA groups
demonstrated a significant decrease when compared to
the control group (p = 0.007). The silencing of the STMN1
siRNA rate was 87.5%, with the gene silencing calculation
method for applied biosystems (Figure 3A-B).
A total of 41 genes were successfully analyzed. The STMN1
silencing markedly suppressed the proliferation-invasion
related claudin7 (CLN7), fibroblast growth factor8
(FGF8), hypoxia-inducible factor1 (HIF1A), hepatocyte
growth factor (HGF), hypoxia-inducible factor 1, alpha
subunit (HIF1A), matrix metallopeptidase 2 (gelatinase A)
(MMP2), matrix metallopeptidase7 (matrilysin, uterine)
(MMP7); apoptosis-related genes caspase1 (CASP1), and

caspase7 (CASP7), and caspase8 (CASP8) and autophagyrelated ATG2 autophagy-related two homolog A (ATG2A),
(ATG5), Microtubule-associated protein 1 light chain 3
alpha (MAPILC3A), Unc-51-like kinase 1 (C. Elegans)
(ULK1) gene expressions (p < 0.05) as shown in Table 5.
Interestingly, the STMN1 silencing has only upregulated
the expression of cathepsin D (fold change: 5.242).
3.4. siRNA-mediated STMN1 silencing induced
apoptosis via the caspase 3 pathway
To determine the possible apoptotic and autophagic
mechanism of STMN1 contributing to PCa cells, we
examined CASP3 and Lc-3 protein expression by using
western blot analysis. The experiment was divided
into three groups as transfection reagent (Control; C),
scrambled si RNA group (Sc-siRNA), and STMN1 siRNA
groups (STMN1-siRNA). Results revealed that CASP3
was significantly higher in the STMN1-siRNA group than
in the control and Sc-SiRNA groups. STMN1 silencing
was determined to significantly increase CASP3 protein
expression, but there was no change in LC3 protein
expression (p < 0.001 and p = 0.32) as shown in Figure
4. These results suggested that the inhibition of STMN1
could induce the apoptosis of PC3 cells via the caspase3
pathway.
4. Discussion
Although direct comparative data are not available to
inform treatment decisions, treatment options are very
limited in castration resistance metastatic prostate cancer
(mCRPCa), and in the advanced stage, only taxanes as
cytotoxic therapy have been shown to provide a survival
advantage (Hsu et al., 2020). In the treatment of PCa,
alternative cytotoxic treatment options enzalutamide
and darolutamide are settled in almost every stage of
PCa today (Armstrong, 2018). We also thought about
why cytotoxic chemotherapies are not so effective and
why resistance to taxane treatments is developing in a
short time. Starting from here, we aimed to determine the
molecular mechanisms in PCa, and whether STMN1 has
a place in the carcinogenesis steps, and the results of its
inhibition both in vitro and in vivo, in this study. STMN1,
a named oncoprotein 18, plays an important role through
activation of the PI3K/Akt pathway in many solid tumor
metastases. STMN1 acts as a microtubule destabilizer to
promote cell proliferation, and also it has a role in the
cell signaling pathway. STMN1 has a dual format due to
pleiotropic phenomena. STMN1 acts both decreasing
cancer invasion and promoting carcinogenesis (Williams
et al., 2012).
It is known that STMN1 is intensely expressed in
many cancers such as lung cancer, breast, and prostate
cancer (Friedrich et al., 1995, Golouh et al., 2008, Nie et al.,
2015). It has been reported that overexpression of STMN1
is related to poor prognosis, and resistance to treatments
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Figure 2. A) The receiver operating characteristic curve (ROC) for stathmin1 (STMN1) expression; B) Kaplan–Meier survival
curves stratified by stathmin1 (STMN1) groups.

Table 3. Analysis based on stathmin1 (STMN1) staining results.
Stathmin1
BPH (as a control group)
Case (n)

Case (n, %)

L-STMN1

H-STMN1

15 (100%)

15(100%)

-

75 (100 %)

27 (36 %)

48 (64 %)

0.5 ± 0.13*

1.81 ± 1.63

p-value

0.001ª

Age*

71.53 ± 6.83* 71.36 ± 6.61* 71.69 ± 7.09* 0.92#

<65 years

17 (18.9%)

10 ( 23.8%)

7 (14.6 %)

≥65 years

73(81.1%)

32 (76.2%)

41 (85.4%)

Stage

0.26ë
0.50 ë

Local advanced

35(46.7%)

14 (51.9 %)

21 (43.8 %)

Advanced

40 (53.3%)

13 (48.1%)

27 (56.2%)

Gleason Score

0.11 ë

≥7

45 (60%)

13 (48.1%)

32 (66.7%)

<7

30 (40%)

14 (51.9%)

16 (33.3%)

Progression

0.37 ë

Present

23 (30.7%)

10 (37%)

13 (27.1%)

Absent

52 (69.3%)

17 (63%)

35 (72.9%)

Perineurol invasion

0.50 ë

Positive

35 (46.7%)

14 (51.9%)

21 (43.8%)

Negative

40 (53.3%)

13 (48.1%)

27 (56.2%)

Angiolymphatic invasion

0.57 ë

Positive

31 (41.3%)

10 (37%)

21 (43.8%)

Negative

44 (58.7%)

17 (63%)

27 (56.2%)

Mann–Whitney U test used, * Mean values, ª: T test used, ë: Pearson chi-squared, L: Low, H:
High
#
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Table 4. Cox proportional hazards for the predictor of
survival.
Multivariate analysis
Variable

p-value HR

Age ( < 65 ≥ )

0.013

10.501 1.649–66.88

LDH value

0.046

1.004

1.000–1.008

Progression (+/-)

0.526

0.456

0.040–5.149

Gleason Score

0.177

5.112

0.479–54.530

STMN1

0.169

2.141

0.724–6.327

Pre-PSA

0.012

1.000

1.000–1.000

CI

HR: Hazard ratio, CI: Confidence interval, LDH: Lactic
dehydrogenase enzyme
Pre-PSA: Pretreatment prostate specific antigen,
STMN1: Stathmin1

in many cancers (Friedrich et al., 1995, Hiıeh et al., 2010,
Watanabe et al., 2014). Pharmacological inhibition of
STMN1 in treatments of cancer has been the focus of
interest for many researchers (Sucharita et al., 2006,
Akhtar et al., 2013). Small interfering RNAs (siRNAs)
that stop gene expression and prevent the development
and progression of many cancers became quite famous
in cancer treatment. siRNAs serve as an RNA guide for
proper micro RNA (miRNA) degradation (Kimberly et al.,
2015). Although it has been demonstrated that STMN1

silencing reduced invasion in PCa cell line as in many
cancer types, this is the first study to demonstrate the
effects on the autophagy, apoptosis, and invasion genes
expressions of STMN1 silencing transfection in PC-3 cell
lines. Similar to other studies in the literature, we observed
a positive relationship between increased tumor burden
and overexpression of STMN1 immunohistochemically, in
the present study (Mistry et al., 2005, Akhtar et al., 2013).
We examined the effects of siRNA-mediated STMN1
silencing on the expression of main autophagy, invasion,
and apoptosis pathway-related genes (BAK1, BCL2, CASP,
CTSB, FGF8, MMP2, AMBRA1, ATG2-5, ULK1, etc.). In
the current study, although we observed that silencing
of STMN1 with siRNA knockdown all of some invasion,
autophagy, and apoptosis gene expressions in the PCa cell
line, the most significant knockdown was in the invasion
genes.
It is generally known that cancer develops as a result
of an increase in cell proliferation and a decrease in
apoptotic mechanisms. Cancer cells try to escape the cell
death pathway by increasing antiapoptotic mechanisms
or by inactivating proapoptotic mechanisms. Apoptosis
mechanisms are activated through two different pathways
called intrinsic and extrinsic. Both of these pathways
activate a series of caspases, targeting and lysing key cellular
proteins. Decreased functions of caspases constitute one of
the escape mechanisms from apoptosis. Caspases (CASP)
are classified according to their structural features as

Figure 3. Heat map of the effects on gene expression after the transfection stathmin1 (STMN1) siRNA in PC-3 cell line. The mRNA
expression obtained using qPCR for the targets selected from the genes in Table 4 is shown as a graph of the profile of the heat map.
Genes clustered according to their expression patterns. The red color on the heat map indicates genes that are highly expressed compared
to control; green color, genes that are expressed at a low level, whereas black color represents genes that are equal to the control.
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Table 5. mRNA fold change and p-value in the PC-3 cell line compared to the control group after stathmin1 (STMN1) siRNA transfection.
Negative control

STMN1 siRNA

Symbol

Name

mRNA fold chance p-value mRNA fold charge p-value

APAF1

Apoptotic peptidase activating factor 1

1.815

0.083

1.223

0.458

BAK1

BCL2-antagonist/killer 1

1.404

0.245

0.901

0.682

BAX

BCL2-associated X protein

1.434

0.223

0.908

0.701

BCL2

B-cell CLL/lymphoma 2

1.035

0.898

0.664

0.177

CASP1

Caspase 1, apoptosis-related cysteine peptidase

0.877

0.615

0.325ab

0.021

CASP2

Caspase 2, apoptosis-related cysteine peptidase

0.986

0.953

0.521

0.069

CASP3

Caspase 3, apoptosis-related cysteine peptidase

1.266

0.394

1.347

0.292

CASP7

Caspase 7, apoptosis-related cysteine peptidase

0.914

0.727

0.476a

0.046

CASP8

Caspase 8, apoptosis-related cysteine peptidase

0.865

0.581

0.359ab

0.025

DFFA

DNA fragmentation factor, 45kDa, alpha polypeptide

0.732

0.277

0.607

0.121

ADAMTS1 ADAM metallopeptidase with thrombospondin type 1 motif, 1 1.007

0.983

0.674

0.188

CD44

CD44 molecule (Indian blood group)

0.933

0.786

0.570

0.095

CDH1

Cadherin 1, type 1, E-cadherin (epithelial)

0.529

0.073

0.674

0.188

CDH2

Cadherin 2, type 1, N-cadherin (neuronal)

0.986

0.953

1.240

0.430

CDH6

Cadherin 6, type 2, K-cadherin (fetal kidney)

0.779

0.368

0.540

0.078

CDH11

Cadherin 11, type 2, OB-cadherin (osteoblast)

0.946

0.827

0.603

0.118

CLDN7

Claudin 7

0.824

0.471

0.493a

0.049

CSF3

Colony stimulating factor 3 (granulocyte)

0.693

0.216

0.591

0.109

CTSB

Cathepsin B

0.847

0.532

0.779

0.362

CTSD

Cathepsin D

1.705

0.106

5.242ab

0.009

FGF8

Fibroblast growth factor 8 (androgen-induced)

0.629

0.142

0.339a

0.022

HGF

Hepatocyte growth factor (hepapoietin A; scatter factor)

0.732

0.277

a

0.392

0.031

HIF1A

Hypoxia inducible factor 1, alpha subunit

0.514

0.067

0.454a

0.045

MMP1

Matrix metallopeptidase 1 (interstitial collagenase)

0.889

0.651

0.669

0.182

ab

MMP2

Matrix metallopeptidase 2 (gelatinase A)

0.717

0.252

0.339

0.022

MMP7

Matrix metallopeptidase 7 (matrilysin, uterine)

0.747

0.305

0.314ab

0.019

MMP10

Matrix metallopeptidase 10 (stromelysin 2)

1.301

0.347

1.231

0.444

MMP11

Matrix metallopeptidase 11 (stromelysin 3)

0.595

0.114

1.028

0.922

MMP13

Matrix metallopeptidase 13 (collagenase 3)

0.986

0.953

0.779

0.362

MMP14

Matrix metallopeptidase 14 (membrane-inserted)

0.717

0.252

1.165

0.568

TGFB1

Transforming growth factor, beta 1

0.551

0.085

1.064

0.816

TIMP2

TIMP metallopeptidase inhibitor 2

0.637

0.151

0.563

0.090

AMBRA1

Autophagy/beclin-1 regulator 1

0.674

0.191

1.347

0.292
0.042

ATG2A

ATG2 autophagy related 2 homolog A (S. cerevisiae)

0.732

0.277

0.444

ATG3

ATG3 autophagy related 3 homolog (S. cerevisiae)

0.774

0.356

0.747

0.299

ATG5

ATG5 autophagy related 5 homolog (S. cerevisiae)

0.660

0.175

0.359a

0.025

ATG7

ATG7 autophagy related 7 homolog (S. cerevisiae)

0.835

0.501

1.257

0.403

ATG10

ATG10 autophagy related 10 homolog (S. cerevisiae)

0.607

0.124

0.664

0.177

MAP1LC3B Microtubule-associated protein 1 light chain 3 beta

0.824

0.471

0.637

0.148

ULK1

Unc-51-like kinase 1 (C. elegans)

0.563

0.092

0.135

0.008

UVRAG

UV radiation resistance associated gene

1.007

0.983

0.616

0.128

a

ab

Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a housekeeping gene for the mRNA expression analysis. a p < 0.05
versus control group. b p < 0.05 versus negative control group.
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Figure 4. Western blot analysis of caspase 3 and LC-3 proteins in PC-3 cell line. The β-actin was used as
an internal control. PC-3 cells were treated with Sc-siRNA and stathmin1 (STMN1)-siRNA for 48 h. The
densitometer-intensity data of the protein bands of each blot is represented as mean ± SEM from three
independent experiments. a letter p < 0.05 versus control as measured by one-way ANOVA test.

inflammatory CASPs such as CASP 1, 4, and 5, initiator
CASPs such as CASP 2, 8, 9, 10, and effector CASPs such
as CASP 3, 6, 7 (Bildik et al., 2018). In our study, we found
that the levels of all of CASPs classes, which we expected
to increase with siRNA-mediated STMN1 silencing,
decreased. It was observed that patients with gastric cancer
with CASP 3 expression had a better prognosis than those
without; however, in this study CASP3 was unaffected by
siRNA-mediated STMN1 silencing (Huang et al., 2018).
Similarly, it was determined that there was a decrease in
the levels of CASP8 in patients with breast cancer. In our
study, we found that the levels of CASP8 decreased after
siRNA-mediated STMN1silencing, which we expected
to increase with siRNA-mediated STMN1 silencing
(Aghababazadeh et al., 2017). It has been observed in
studies that siRNA-mediated STMN1 silencing increases
the effect of cytotoxic agents such as taxanes, working by
affecting the tubules (Alli et al., 2021). Meng et al. showed
that the efficacy of docetaxel, used in the treatment of
gastric cancer, was significantly increased when used in
combination with siRNA-mediated STMN1 silencing in
both in vivo and in vitro (Meng et al., 2016). In this study,
STMN1 silencing was determined to significantly increase
caspase 3 protein expression, but not change microtubuleassociated proteins 1A/1B light chain 3B protein expression
(p < 0.001 and p = 0.32), respectively. Although PCR and
western blot results were not compatible with each other,
we thought that STMN1 was significantly effective in
caspase the apoptotic pathway in PCa due to the increase
of CASP3 after siRNA-mediated STMN1 silencing via
western blot analysis. Wang et al. also showed that apoptosis
increased via upregulated caspase genes especially CASP3

by knockdown of STMN1 in squamous cell carcinoma of
head and neck, and gall bladder carcinoma (Wang et al.,
2016). Again similarly, Wu and colleagues determined
that combination paclitaxel and siRNA-mediated STMN1
silencing increased to tending of apoptosis in nasopharynx
carcinoma cell lines (Wu et al., 2014). The inconsistency
between PCR and western blot results in apoptosis-related
genes suggests that the effect of STMN 1 silencing on
apoptosis is not very clear. In addition, the pleiotropic
nature of STMN1 may contribute to this situation. The
direction of the oncogenesis is determined according to
the direction of the wind. More detailed studies on this
subject will illuminate the gray zones.
Autophagy acts bidirectionally in tumor cells. In the
limited stage, it prevents distant metastasis by preventing
necrosis and inflammation. In the advanced stage of
cancer, it helps the disintegration of the EMT zone, and
cancer cells stay adhere-reside or dormant in the new
microenvironment. There is a strong relationship between
the apoptotic and autophagy pathways. In the presence of
any autophagy defects, cancer transformation is facilitated
with adverse microenvironmental conditions; this
promotes the survival, proliferation, and growth of cancer
cells (Cristofani et al., 2014). Studies with animal models
have shown that autophagy suppresses the growth of
benign tumors but supports the progression of malignant
tumors (Onorati et al., 2018). In the current study, ATG2A,
ATG5, and ULK1 autophagy-related genes are inhibited; as
a result, autophagy was not markedly induced by siRNAmediated STMN1 silencing.
Wang and colleagues showed that the invasion of PCa
reduced by silencing of STMN1 in gallbladder cancer;
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however, they used miRNA 34a for STMN1 inhibition in
their study (Wang et al., 2016). Similarly, invasion-related
genes including CLDN7, FGF8, HIF1A, HGF, MMP2-7
proteins were downregulated via siRNA-mediated STMN1
silencing in the present study. From these deductions, we
suggest that STMN1 has the main role in the invasion of
PCa.
FGF8 has a role in many processes, including cell
division, regulation of cell growth, and maturation.
Overexpression of FGF8 has been shown to increase
tumor proliferation rate and angiogenesis (Mattila et al.,
2007). Especially, it has been observed to be higher in
hormonal-dependent (i.e. androgen-induced) prostate
and breast cancers (Tanaka et al., 1995). FGF8 has been
associated more frequently in events with hematogenous
spread and bone metastases in advanced stage PCa. In
our study, we also determined that FGF8 knockdown by
STMN1 with siRNA. We concluded that STMN1 plays role
in the dissemination of PCa via hematogenous spread.
Tight junctions are very important for the continuity of
EMT. EMT loss is essential in the processing mechanism
of certain epithelial cancers. CLDN family is likely the
cornerstone for this barrier against invading tumoral
processing. In a previous study, it was determined that
CLDN4 is down-regulated, CLDN 2, 3, 5 upregulated, and
CLDN7 does not change in PCa (Malheiros et al., 2011).
While overexpression CLDN7 is associated with some
cancers, it has been found knockdown of CLDN7 in some
cancers such as breast cancer and H. pylori-associated
gastric cancers (Dahiya et al., 2011, Singh et al., 2015,
Wroblewski et al., 2015). Malheiros and colleagues also
deducted that CLDN7 was upregulated by androgens in
PCa, from in their study (Malheiros et al., 2011). Similarly,
we saw that CLDN7 can be silenced by siRNA-mediated
STMN1 silencing in our study.
It has been known that HIF1 is activated under hypoxic
conjectures’ in tumor cells, but sometimes HIF1A activation
can occur under oxygen-independent conditions. Cancerspecific alterations including genetic variations, mutations
may cause this situation to occur (Luo et al., 2018).
AHIF1A pathway has also been implicated in the
etiopathogenesis of mCRPCa. Tran and colleagues, in
their study, showed that a prognostic relationship between
AR, HIF1A, hypoxia, and progression status in PCa (Tran
et al., 2020). We showed that HIF1A might be sustained by
STMN1 with siRNA in the present study.
Hepatocyte growth factor (HGF) regulates cell growth,
cell motility, morphogenesis, and angiogenesis via the
tyrosine kinase pathway through a proto-oncogene c-Met
receptor. Recent studies have shown that Wnt/β–catenin
signaling and HGF/Met are activated in metastatic
processing PCa, including mCRPCa (Aldahl et al., 2020).
HGF is overexpressed and associated with poor prognosis,
formation of bone metastases in advanced-stage PCa cases,
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and it has been associated with lymph node involvement
in locally advanced PCa (Pisters et al., 1995). In this study,
it was shown that HGF can be suppressed by STMN1 with
siRNA.
Epithelial-mesenchyme transition (EMT) is an
important barrier to the invasion of tumor cells and also
plays a role in cell adhesion, cell-to-cell cross-talk, and
cell differentiation. When these barriers are disrupted
through such as serine proteases, threonine proteases,
and matrix metalloproteinase (MMP), cell integrity is
broken and metastases occur. Geng et al. showed that
MMPs have important roles in the stages of tumor genesis
and progression of the PCa (Geng et al., 2020)). The
researchers determined that MMP-2 expression detected
in the presence of micrometastases in the bone marrow
after radical prostatectomy indicated a higher Gleason
score, shorter PFS, the presence of circulating PCa cells
(Murray et al., 2020). Similarly, Tregunna and colleagues
described that MMP7 has prognostic value for survival
and response to treatment chosen in PCa (Tregunna et al.,
2020). Similar to the mentioned studies, we have seen that
MMP2-7 might be knockdown by STMN1 with siRNA in
the invasion of the PCa and that invasive patterns can be
managed in this way.
The present study has several limitations. Firstly, the
number of patients diagnosed with PCa was limited. If we
had more cases, we could talk about statistical significance
in Cox regression analysis more comfortably. Secondly,
we did not investigate other probable interweaving
modifications of these genes and genetic variations that
could occur along the cell lines. Thirdly, only one PCa cell
line was used. Fourthly, examination of STMN1 was only
conducted by immunohistochemistry, not blood samples.
In conclusion, it was determined that histopathological
samples obtained from PCa patients were STMN1
immune reactive. It was observed that invasion genes
were suppressed more than apoptosis, and autophagyrelated genes by siRNA-mediated STMN silencing in
the PCa cell line. Lower STMN1 is a favorable factor in
terms of survival. The siRNA-mediated STMN1 silencing
suppressed invasion of the PCa cell line. These findings
indicated that siRNA-mediated STMN1 silencing might
serve as a potential therapeutic target for PCa.
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